Martha F. Ferger

Synthesis and some pharmacological properties of [I-β-mercaptopropionic acid, 2-(3,5-dibromo-l-tyrosine)]-8-lysine-vasopressin☆

Abstract The title compound, [1-β-mercaptopropionic acid, 2-(3,5-dibromo- l -tyrosine)]-8-lysine-vasopressin (X), was synthesized by condensation of Pro-Lys(Boc)-Gly-NH 2 with the cyclic peptide [1-β-mercaptopropionic acid, 2-(3,5-dibromo- l -tyrosine)]-pressinoic acid. X has no oxytocic, avian vasodepressor, pressor, or antipressor activities, but is a weak inhibitor of the responses to oxytocin in the oxytocic and avian vasodepressor assays. Its pharmacological properties are qualitatively identical to those of the corresponding analog of oxytocin, although it is a less potent antagonist than the latter compound.

The synthesis and biological properties of [I-deaminopenicillamine]-oxytocin deuterated in the I-position

Abstract This paper describes the synthesis of 3- S -benzylmercapto-3-methyl- d 8 -butanoic-2,2,4,4,4- d 5 acid ( S -benzyl-deaminopenicillamine- d s ) and [1-deaminopenicillamine- d s ]-oxytocin. Within experimental error the deuterated oxytocin analog possessed the same anti-oxytocic activity as the protio derivative [1-deaminopenicillamine]-oxytocin.